Tango Therapeutics, Inc. has grown revenue 21% a year over three years and 52% a year over five. Revenue growth, 3-year annual rate: +21% (Biotechnology median +17%). Revenue growth, 5-year rate: +52%, growth has slowed since the five-year average. Years of annual history on file: 6, FY2020 to FY2025, as filed.

TNGXTango Therapeutics, Inc.

Healthcare

$23.82+213% 1Y

$23.82

$6.9152 weeks$32.90

Is it growing?

Good

Revenue growing +146% year on year. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data

Revenue trend+146% in a yearSEC EDGAR · Jun 30, 2026

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is TNGX growing?

Tango Therapeutics, Inc. has grown revenue 21% a year over three years and 52% a year over five.

+21%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +52%
Revenue growth, 5-year rate · +21% over three · growth has slowed since the five-year average
Years of annual history on file: 6
Years of annual history on file · FY2020 to FY2025, as filed

Details›